Friday Happy Hour Update: Two New SPACs + BRAC
by Kristi Marvin on 2019-06-28 at 6:23pm

And one of the new SPACs has a 1/4 warrant… this is BIG news.

In the interest of it being the happiest of hours…a brief summary has been provided below.  A more thoughtful analysis will be provided later.


CONYERS PARK II ACQUISITION CORP.

For the first time EVER, we have a SPAC trying for a 1/4 warrant.  This is wild…and it’s probably going to make a few warrant players want to drink heavily tonight.  At $400 million, this is a pretty big SPAC for the underwriters to have sell a 1/4 warrant, but if they’re successful, you can guarantee that other teams will try it and that will not make warrant investors happy.  Having said that, the Conyers Park II team was responsible for one of the most successful SPAC combinations ever – Simply Good Foods (SMPL) – which closed today at a whopping $24.08.

Other headline terms:  100% in trust, 24 months, warrant call for shares at $10.00, no crescent term.  Deutsche Bank is left lead, Goldman Sachs is right lead.

 

OAKTREE ACQUISITION CORP.

Another tier-1 SPAC was also filed tonight in the form of Oaktree Acquisition Corp. Oaktree, the sponsor, is a leading global investment management firm with approximately $118.6 billion in assets under management.  Hence, we’ve got A++ terms:  24 months, 1/3 warrant, warrant call for share term, Crescent term at $9.20.  Credit Suisse is left lead underwriter, and Deutsche Bank has a double header tonight as right lead.

The team is an impressive array of heavy hitters, with Patrick McCaney, Alexander Taubman, and Matthew Pendo leading the team.  However, if this wasn’t their first SPAC, I bet their bankers would have gone for a 1/4 warrant as well.  Especially given that DB is an underwriter on both.

Note:  Andrea Wong, who is on Oaktree Acquisition’s board is also on Social Capital Hedosophia’s board, but they have yet to announce their combination.

 

BLACK RIDGE ACQUISITION CORP.

Black Ridge files a definitive proxy and fills in some blanks for us.  First up, they are only going for a one-month extension to August 10th, and they are pulling a “Gig” by only offering $30,000 to trust to extend.  As a result, we won’t know the exact amount per share to be contributed until post-vote when they count the redemptions.

More to come on all of the above, but for now….enjoy the weekend.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved